机器人辅助与开放经胸食管切除术后的肺功能纵向变化及肺部并发症比较
该回顾性队列研究纳入1917例食管癌根治术患者,比较机器人辅助胸腹腔镜食管切除术(RATE)与开放经胸食管切除术(OTE)术后1年内肺功能变化及肺部并发症(PPCs)。
要点
- RATE组术后3个月FVC(%预计值)下降6.1%,OTE组下降14.5%;FEV1(%预计值)分别下降4.6%和11.5%。
- 术后12个月RATE组FVC(%预计值)下降3.8%,OTE组下降12.3%;FEV1(%预计值)分别下降0.9%和7.3%。
核心结论
- RATE较OTE在术后1年内显著更好地保留肺功能并减少PPCs,早期及接受新辅助治疗者获益最大。
研究设计与样本
- 韩国Samsung Medical Center单中心回顾性队列研究,纳入1917例食管癌根治术患者,OTE组1485例(77.5%),RATE组432例(22.5%)。
- 术前及术后3、6、12个月行肺量计和一氧化碳弥散量测定,采用线性混合效应模型分析纵向变化,多变量logistic回归评估手术方式与PPCs关联。
主要发现
- 术后3个月FVC(%预计值)OTE组下降14.5%、RATE组下降6.1%;FEV1(%预计值)分别下降11.5%和4.6%。
- 术后12个月FVC(%预计值)OTE组下降12.3%、RATE组下降3.8%;FEV1(%预计值)分别下降7.3%和0.9%。
- 接受新辅助治疗者获益更明显,术后3个月FVC(%预计值)OTE组下降14.8%、RATE组下降3.3%。
关键数值与推荐
- 术后3个月FVC(%预计值)降幅:OTE组14.5% vs RATE组6.1%;FEV1(%预计值)降幅:OTE组11.5% vs RATE组4.6%。
- 术后12个月FVC(%预计值)降幅:OTE组12.3% vs RATE组3.8%;FEV1(%预计值)降幅:OTE组7.3% vs RATE组0.9%。
临床怎么用
- 对合适食管癌患者,RATE可作为优先选择,尤其PPCs高风险及接受新辅助治疗者。
- 术后早期(3个月内)是肺功能保护获益最显著时段,应加强该阶段呼吸管理。
局限性
- 单中心回顾性设计,可能存在选择偏倚。
- 仅纳入有肺功能检测数据的患者,可能存在信息偏倚。
- 基线DLCO组间存在差异,虽经校正仍可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Esophagectomy is associated with significant postoperative pulmonary complications (PPCs), occurring in 20% to 50% of patients. Although robot-assisted thoracoscopic esophagectomy (RATE) is a promising alternative to open transthoracic esophagectomy (OTE), comprehensive data on longitudinal pulmonary function recovery and clinical outcomes remain limited. This study aimed to compare the changes in pulmonary function and PPCs between RATE and OTE over the first year after surgery. METHODS: This retrospective cohort study was conducted at Samsung Medical Center, Seoul, South Korea, and included 1917 patients with esophageal cancer who underwent curative-intent esophagectomy and for whom pulmonary function test data were available. Of these, 1485 (77.5%) underwent OTE and 432 (22.5%) underwent RATE. Spirometry and diffusing capacity of the lung for carbon monoxide measurements were performed preoperatively and at 3, 6, and 12 months postoperatively. Linear mixed-effects models were used to analyze longitudinal changes, adjusting for age, sex, stage, and neoadjuvant therapy. Multivariable logistic regression was used to evaluate the association between surgical approach and PPCs. RESULTS: Baseline pulmonary functions were similar for the groups, except for greater diffusing capacity of the lung for carbon monoxide in the RATE group (19.2 vs 17.7 mL/min/mm Hg, P < .001). RATE was associated with significantly better preservation of pulmonary function across all parameters. At 3 months, forced vital capacity (FVC, % predicted) decreased by 14.5% in the OTE group versus 6.1% in the RATE group and FEV1 (% predicted) by 11.5% versus 4.6%. By 12 months, FVC (% predicted) declined by 12.3% versus 3.8% and FEV1 (% predicted) by 7.3% versus 0.9%, respectively. The benefits were more pronounced in patients receiving neoadjuvant therapy, with FVC (% predicted) declining by 14.8% in the OTE group versus 3.3% in the RATE group at 3 months. PPCs occurred less frequently in the RATE group (28.8% vs 39.4%, P < .001). After comprehensive adjustment, RATE was associated with a 27% reduction in complication risk (adjusted odds ratio, 0.73; 95% CI, 0.57-0.93; P = .011), with consistent benefits observed in both upfront surgery and neoadjuvant therapy subgroups. CONCLUSIONS: RATE can significantly better preserve pulmonary function and reduce PPCs compared with OTE throughout the first year after surgery, with the greatest benefits in the early postoperative period and for patients receiving neoadjuvant therapy. This supports the use of RATE as the preferred approach for appropriate candidates with esophageal cancer, particularly those at greater risk for PPC.
引用
- Jeon YJ, Kang D, Moon S, et al. Longitudinal pulmonary function changes and pulmonary complications after robot-assisted thoracoscopic versus open transthoracic esophagectomy. J Thorac Cardiovasc Surg. 2026. PMID: 42142648. doi:10.1016/j.jtcvs.2026.04.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。